| abstract |
The present invention provides an insulin lispro compound that exhibits high solubility at physiological pH, has a long action time, and is excellent in pharmacokinetics and pharmacodynamics. A pegylated insulin lispro compound PEGylated with polyethylene glycol having a molecular weight in the range of 17.5-40 kDa, a pharmaceutically acceptable phenolic preservative, and a hexamerization of the pegylated insulin lispro compound. A pharmaceutical composition comprising a sufficient amount of zinc and further one or more pharmaceutically acceptable excipients, diluents or carriers. [Selection figure] None |